The goal of this program is to improve management of breast cancer using antibody drug conjugates. After hearing and assimilating this program, the clinician will be better able to:Assess use of trastuzumab emtansine compared with trastuzumab in high-risk breast cancer patients as observed in the KATHERINE trial.Explain the results using trastuzumab deruxtecan in patients with human epidermal growth factor receptor-low breast cancer, per the DESTINY-Breast04 trial.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Oncology
- Start Date: 2024-08-29 05:00:00
- End Date: 2024-08-29 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.75 hours
- MOC Credit Details: ABIM - 0.75 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Jointly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest